UK health technology assessor the National Institute for Health and Care Excellence (NICE) has issued Final Draft Guidance ...

BMS’ Breyanzi and Amgen’s Blincyto will now be available to patients in England with certain types of blood cancer.

Galapagos shifts to CAR-T therapy with GLPG5101, targeting pivotal trials by 2026. Click here to find out why I rate GLPG ...

We recently published a list of the 10 Best Performing Healthcare Stocks So Far in 2025. In this article, we are going to ...

NICE's initial guidance on Breyanzi concluded it was not a cost-effective option for patients, but the agency said this ...

Genmab (GMAB) announced that the Japan Ministry of Health, Labour and Welfare has approved EPKINLY or epcoritamab, for the treatment of ...

We recently published a list of 10 Stocks Kick Off Trading Week With Losses. In this article, we are going to take a look at ...

Baidu, Inc. (NASDAQ:BIDU) retreated on Tuesday, losing 7.51 percent to close at $90.16 apiece as investors unloaded ...

Explore how T cell engagers could transform cancer and autoimmune treatments through promising trials and key collaborations.

TEM basically mixes genomic and clinical data with AI. This is at the core of their new offerings for precision diagnostics ...

Tempus AI (NASDAQ: TEM) is a leader in precision medicine and artificial intelligence (AI) in the healthcare sector. Tempus ...

The addition of epcoritamab-bysp to standard chemotherapy significantly improved response and survival for patients with ...